Riskpilot← Back to searchSign inGet full accessSweorto AB
ABActiveOrg 5566261821S:T Johannesgatan 2 4trWholesale of pharmaceutical and medical goods · NACE 4646Est. 20027 employees
Revenue 2024
SEK 35,6M
+2% vs 2023
EBITDA margin
3.5%
-26% vs 2023
Equity ratio
36.1%
Financial strength
Net profit 2024
SEK 989K
-25% vs 2023
| Revenue | SEK 35,6M | +2% |
| EBITDA | SEK 1,2M | -26% |
| Net profit | SEK 989K | -25% |
| Total assets | SEK 15,4M | +18% |
| Equity | SEK 5,5M | +22% |
| Employees | 7 | — |
Legal name
Sweorto AB
Org number
5566261821
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 april 2002
Share capital
SEK 100 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bederiva försäljning av dentalprodukter och därmed förenlig verksamhet.
Address
S:T Johannesgatan 2 4tr
Email
rakenskap@sweorto.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 9 100 | 7 867 | 17 580 | 24 536 | 27 842 | 34 807 | 35 563 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 48 | 377 | 819 | 426 | 319 | 601 | 635 | 712 | 1 667 | 1 235 |
| Depreciation & amort. | −12 | −8 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 36 | 369 | 819 | 426 | 319 | 601 | 635 | 712 | 1 667 | 1 235 |
| Net financials | −11 | −5 | −2 | −3 | −4 | −6 | −4 | 7 | 56 | 102 |
| Profit before tax | 24 | 364 | 816 | 423 | 315 | 595 | 631 | 720 | 1 722 | 1 337 |
| Tax | −0 | −0 | −131 | −116 | −90 | −137 | −155 | −215 | −403 | −348 |
| Net profit | 24 | 364 | 685 | 307 | 225 | 458 | 476 | 505 | 1 319 | 989 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 987 | 1 623 | 2 691 | 3 560 | 3 793 | 9 314 | 7 235 | 12 920 | 12 986 | 15 364 |
| Equity | 211 | 575 | 1 261 | 1 568 | 1 793 | 2 251 | 2 727 | 3 232 | 4 551 | 5 540 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 776 | 1 048 | 1 430 | 1 992 | 2 000 | 7 063 | 4 507 | 9 688 | 8 435 | 9 824 |
| Total debt | 776 | 1 048 | 1 430 | 1 992 | 2 000 | 7 063 | 4 507 | 9 688 | 8 435 | 9 824 |
EBITDA margin
3.5%
This company
15.8%
Market median
-78% vs market
20152024
Equity ratio
36.1%
This company
38.2%
Market median
+5% vs market
20152024
Return on equity
17.9%
This company
18.4%
Market median
+3% vs market
20152024
Net profit margin
2.8%
This company
8.1%
Market median
-65% vs market
20152024
Asset turnover
2.31×
This company
1.12×
Market median
+106% vs market
20152024
Debt / equity
1.77×
This company
0.62×
Market median
-185% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-07-01 – 2015-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AM Chief Auditor | Chief Auditor | 2021 | — | — |
CS Authorized Recipient of Service | Authorized Recipient of Service | 2020 | — | — |
PT Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nobel Biocare AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOBEL BIOCARE SERVICES AG
Sweorto AB Board members of Sweorto AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Annie Maria Sande | Chief Auditor | 0 companies |
| Carl-Henrik Stefan Langdal | Authorized Recipient of Service | 0 companies |
| Pär Thomas Nilsson | Chief Auditor | 0 companies |
| Xavier Cherbavaz | Chairman | 0 companies |
| Maria Luisa Caggiula | Board of Directors | 0 companies |
| Karel Budka | Board of Directors | 0 companies |
| Steven Albert Put | Board of Directors | 0 companies |
| Hans Joakim Bursell | Chairman | 0 companies |
| Karel Rajchert | Board of Directors | 0 companies |